TransMedics Director David Weill Purchases $109,000 of Stock -- Should Investors Buy Too?
Key Points
The director acquired 1,336 shares for a total value of ~$109,000 on Sept. 11, 2026.
The purchase involved shares equal to 9% of the stake held before the filing.
The transaction was executed via direct ownership, bringing the total direct position to 16,392 shares.
Shares were purchased at $81.63 per share, while the stock was priced at $82.18 at the Sept. 11, 2026, market close.
David Weill, a Director at TransMedics Group, Inc. (NASDAQ:TMDX), purchased 1,336 shares of common stock on Sept. 11, 2026. SEC Form 4 filing
Transaction summary
| Metric | Value |
|---|---|
| Transaction value | $109,000 |
| Shares purchased (directly held) | 1,336 |
| Post-transaction shares (directly held) | 16,392 |
| Post-transaction value | $1.35 million |
Transaction value based on SEC Form 4 weighted average purchase price ($81.63); post-transaction value based on Sept. 11, 2026, market close ($82.18).
Key questions
- How did this transaction affect the director's total equity stake?
The acquisition of 1,336 shares, representing 9% of the shares held prior to the filing, increased the total direct holdings to 16,392 shares. - What is the current market valuation of the insider's position?
Based on the Sept. 14, 2026, market close price of $85.86, David Weill's 16,392 shares are valued at ~$1.4 million. - What performance context surrounded the acquisition?
The purchase was executed as the stock recorded a one-year return of -30% through the Sept. 11, 2026, transaction date. - What are the primary operations of TransMedics Group?
The company is a commercial-stage medical technology enterprise that focuses on organ transplant therapy through its Organ Care System, which is designed to monitor and optimize donor organs.
Company Overview
| Metric | Value |
|---|---|
| Share Price (as of market close 2026-09-29) | $82.73 |
| Market Capitalization | $2.7 billion |
| Revenue (TTM) | $668.5 million |
| Net Income (TTM) | $151.7 million |
Company Snapshot
- TransMedics Group, Inc. develops and commercializes the Organ Care System (OCS), a portable medical device that perfuses, optimizes, and continuously monitors donor organs to improve transplant outcomes and expand the donor organ pool.
- The company generates revenue through the sale of OCS devices and related consumables, service agreements, and licensing arrangements with transplant centers and healthcare systems globally.
- TransMedics serves transplant centers, hospitals, and organ procurement organizations in North America and internationally, targeting institutions performing heart, lung, and liver transplantation procedures.
TransMedics Group is a commercial-stage medical technology enterprise with a market capitalization of $2.7 billion and TTM revenues of $668.5 million, demonstrating significant scale in the organ transplantation technology sector. The company's Organ Care System represents a differentiated approach to donor organ preservation, using proprietary perfusion technology to recreate near-physiological conditions and extend the viability window of organs. This innovation positions TransMedics as a critical enabler of expanded criteria donor utilization and improved transplant outcomes, providing a competitive advantage in addressing the substantial global shortage of viable donor organs.
What this transaction means for investors
While it is great to see some open-market purchases by a director at TransMedics, I wouldn't let the buy serve as anything more than a tiebreaker for investors considering scooping up a few shares.
First, while it is a positive sign, it was only a $109,000 purchase, so this isn't a groundbreaking figure in the context of the broader stock market. Sure, it's a ton of money to me, but in publicly traded stock terms for a multi-billion-dollar company, it isn't overwhelming.
That said, it is a nice vote of confidence from an insider at the company and reinforces the notion that management believes in TMDX stock's promising operations. TransMedics is guiding for 22%-25% sales growth in 2026 and remains the fastest-growing in its niche.
As TransMedics iterates upon its existing liver, heart, and lung platforms, tests a new kidney OCS, and continues expanding internationally while scaling its logistics unit, the company remains a buy in my eyes -- and Director Weills' purchase is a nice cherry on top for me.
Currently, TMDX stock trades at 22 times cash from operations, which isn't outrageous considering the company's long-term growth potential as it continues to revolutionize and modernize the organ donation process.
Josh Kohn-Lindquist has positions in TransMedics Group. The Motley Fool has positions in and recommends TransMedics Group. The Motley Fool has a disclosure policy.